INGENOL MEBUTATE
Lentigo Maligna
Centre Hospitalier Universitaire de NiceSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Lentigo Maligna cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Imiquimod Melanoma and Skin Cancer Trials Limited | Phase 4 | BBB |
5-ala Joint Authority for Päijät-Häme Social and Health Care | Phase 4 | B |
Cediranib National Cancer Institute (NCI) | Phase 2 | B |
Dinaciclib National Cancer Institute (NCI) | Phase 2 | CCC |
rg4733 National Cancer Institute (NCI) | Phase 2 | CC |
Tazarotene University of Utah | N/A | D |
Same molecule, other indications
INGENOL MEBUTATE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →